

To Control Floating Drug Delivery System in a Simulated Gastric Environment by Adjusting the Shell Layer Formulation

Yu Tung Hsu

National Taiwan University of Science and Technology

Chen Yu Kao

National Taiwan University of Science and Technology

Ming-Hua Ho (✉ mhho@mail.ntust.edu.tw)

National Taiwan University of Science and Technology <https://orcid.org/0000-0001-6620-4207>

Research article

Keywords: gastroretentive drug delivery, core-shell particles, floating beads, chitosan, xanthan gum, anti-bacterial effect

Posted Date: April 6th, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-363794/v1>

License:   This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19

**To Control Floating Drug Delivery System in a Simulated Gastric
Environment by Adjusting the Shell Layer Formulation**

^aYu Tung Hsu, ^cChen Yu Kao*, ^{a,b}Ming Hua Ho*

^aDepartment of Chemical Engineering, National Taiwan University of Science and
Technology, Taipei 10617 Taiwan

^bR&D Center for Membrane Technology, National Taiwan University of Science and
Technology, Taipei 10617 Taiwan

^cDepartment of Biomedical Engineering, National Taiwan University of Science and
Technology, Taipei, 10607, Taiwan

*Co-Corresponded to Ming Hua Ho and Chen Yu Kao

Tel: +886-2-27301255

Fax: +888-2-27301255

Email: mhho@mail.ntust.edu.tw

1 **Abstract**

2 **Background:**

3 Gastroretentive drug delivery system (GDDS) are novel systems that have been
4 recently developed for treating stomach diseases. The key function of all GDDS
5 systems is to control the retention time in the stomach. However, research into the bulk
6 density or entanglement of polymers, especially regarding their effects on drug float
7 and release times, is scarce.

8 **Methods:**

9 In this research, we prepared the floating core-shell beads carrying tetracycline.
10 The ratio of chitosan and xanthan gum in the shell layer was changed to modify polymer
11 compactness. Tetracycline was encapsulated in the alginate core.

12 **Results:**

13 Using scanning electron microscopy (SEM) techniques, we observed that the shell
14 formulation did not change the bead morphology. The cross-sectional images showed
15 that the beads were highly porous. The interaction between anionic xanthan gum and
16 cationic chitosan made the shell layer dense, resisting to the mass transfer in the shell
17 layer. Due to the high mass transfer resistance to water penetration, the longer float and
18 delivery time were caused by the dense surface of the beads. The cell culture
19 demonstrated that floating core-shell beads were biocompatible. Importantly, the beads
20 with tetracycline showed a significant prolonged anti-bacterial effect.

21

22

23

1 **Conclusion:**

2 Research results proved that the floating and releasing progress of core-shell beads
3 can be well controlled by adjusting the shell layer formulation that could promote the
4 function of gastroretentive drugs.

5

6 Keywords: gastroretentive drug delivery, core-shell particles, floating beads, chitosan,
7 xanthan gum, anti-bacterial effect

8

9

10

11

12

13

14

15

16

17

18

19

20

1 **Introduction**

2 Oral administration is the most common drug delivery method as it is
3 multifunctional and convenient [1]. The size of drug carriers is usually adjusted to 1-2
4 mm, allowing the medicine in the stomach to pass through the pylorus and enter into
5 the small intestine [2]. Advances in pharmaceutical techniques have enabled to release
6 drugs in a specific position *in vivo* to lower toxicity, decrease side effects, and promote
7 efficiency. Thus, the gastroretentive drug delivery system (GDDS) has been developed
8 for treating stomach cancer, ulcer and infection. GDDS could keep drugs in stomach
9 for a prolonged period to achieve a specific release, including several types: floating,
10 mucoadhesive, expandable and rafting forming drug delivery systems.

11 The floating drug delivery system (FDDS) is also called a hydrodynamically
12 balanced system (HBS). In FDDS, the drugs carriers float in gastric juice to ensure that
13 drugs do not leave stomach shortly. It efficiently increases drug bioavailability by
14 prolonging the release period. The variation of drug concentrations in blood is also
15 decreased [3]. FDDS is a potential treatment for stomach and duodenum cancers. The
16 density of FDDS carriers must be lower than those of the gastric juice and chymus.
17 Therefore, medicines float and are slowly released in the stomach, compared with the
18 convectional drug delivery methods.

19 Currently, most FDDS would not float for 2-8 h; however, the drug float and
20 release periods need to be prolonged. To obtain improved drug float and release times,
21 previous research studies have widely investigated control of the drug carrier materials.
22 Kawashima [4, 5], Sato [6], Thanoo [7] et al. prepared hollow spheres for FDDS by
23 using the emulsion-solvent diffusion method. These studies focused on controlling the
24 carrier density by solvent diffusion. In particular, polymer porosity dominates the
25 solvent diffusion rates that determining the carrier floating behaviors. Xiaoqiang, Choi

1 and El-Kamel et al. added gas-forming/generating agents in polymers to increase the
2 porosity, and therefore, the floating properties [8-10]. Indeed, the porosity was
3 influenced by the amount of gas-generating agents. According to prior researches, the
4 gas generating agents and solvent diffusion would significantly affect the porosity in
5 FDDS. In contrast, research into the bulk density or entanglement of polymers,
6 especially regarding their effects on drug float and release times, is scarce.

7 In this research, we prepared the core-shell floating particles for GDDS. We used
8 two polymers, chitosan and xanthan gum, as the shell layer, which are cationic and
9 anionic, respectively. Adjusting the chitosan/xanthan gum ratio enabled us to adjust the
10 polymeric entanglement, and allowed us to control the shell layer properties and
11 structures in floating beads. Then, we studied how the shell layer affects the float, release
12 and biocompatibility properties.

13

14 **Materials and Methods**

15 **Materials**

16 Alginic acid sodium salt (medium viscosity), xanthan gum (from *Xanthomonas*
17 *campestris*), NaHCO₃ (sodium bicarbonate powder), chitosan (low molecular weight),
18 tetracycline (>98.0%) were purchased from Sigma-Aldrich (St. Louis, MO). CaCl₂
19 (calcium chloride) and HCl and acetic acid were purchased from J.T. Baker, Japan.
20 Dulbecco's modified eagle medium (DMEM), fetal bovine serum (FBS), penicillin,
21 trypsin was purchased from Gibco Life Technologies (Thermo Fisher Scientific - TW).
22 Kaighn's modification of Ham's F-12 medium was purchased from Manassas, VA, USA.
23 MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) kit was
24 purchased from Carlsbad, CA, USA. Distilled deionized (DI) water was used
25 throughout the experiment.

1 **Preparation of alginate floating beads containing tetracycline**

2 Two solutions were prepared respectively for core-shell beads. One was the
3 alginate solution for core, and the other was the chitosan/xanthan-gum solution for shell.
4 50 mg tetracycline and 200 mg alginate were mixed in 10 ml DI water, and stirred for
5 2 hours to obtain the tetracycline-alginate solution. 200mg NaHCO₃ was then added
6 into alginate solution, and stirred at 500 rpm for 1 hour. On the other hand, chitosan
7 solution was prepared by dissolving chitosan powders in 1 v/v% acetic acid aqueous
8 solution, and xanthan gum solution was prepared by dissolving xanthan gum in DI
9 water. After that, chitosan and xanthan gum solutions were mixed with different
10 chitosan/xanthan-gum ratios of 4:1, 4:2, 4:3, 4:4 and 1:4, where CaCl₂ was also added
11 as the concentration of 1 w/v%. The tetracycline-alginate solution was extruded through
12 a 26-gauge needle into the continuously stirred chitosan/xanthan gum solution, and the
13 solution with floating beads was continuously stirred for 15 minutes. After the beads
14 were collected and washed with DI water, they were vacuum dried for 48 hours, and
15 then stored in 4°C until used. The exact formulations of core and shell layer were
16 described in Table 1.

17

18 **FE-SEM (field emission scanning electron microscope) analysis**

19 SEM (JEOL JSM-6390LV, Japan) images were taken to analyze the morphology
20 of floating beads. The beads were dried at 4°C. After that, the bead samples were spread
21 and fixed on the metal plate with double-sided carbon tape, and a gold layer was then
22 coated on the sample surface under vacuum using an auto-sputter coater for 1 minute
23 under argon atmosphere. The beads morphologies were then observed with SEM. With
24 SEM images, the bead diameters were measured by Image J software.

25

26

1 **Swelling and floating test**

2 The swelling percentage of beads was determined by measuring the extent of
3 swelling of the polymer matrix in pH2 aqueous solution. The weight of dried beads was
4 recorded. After the immersion in pH2 buffer for 1, 2, 4, 6, 8, 12 and 24 hours, water on
5 bead surfaces was removed by filter paper and the weight beads were measured again.
6 The swelling percentage was calculated by using the following equation.

$$7 \quad \text{Swelling index (\%)} = \frac{\text{Weight of beads after swelling} - \text{Dry weight of beads}}{\text{Dry weight of beads}} \times 100\%$$

8 For the floating analysis, twenty dried beads were kept in pH2 buffer for 24 hours
9 with continuous shaking. At 1st, 2nd, 4th, 6th, 8th, 12th and 24th hour, the floating
10 percentage was calculated according to following equation:

$$11 \quad \text{Floating percentage (\%)} = \frac{N_f}{N_f + N_s} \times 100\%$$

12 N_f : number of floating beads; N_s : number of settled beads

13

14 **In vitro release and encapsulation efficiency of tetracycline**

15 The dry beads were immersed in pH2 buffer in the dynamic gastric simulator [11].
16 After 2, 4, 6, 8, 12 and 24 hours, 10ml solution was taken out and analyzed by UV/VIS
17 spectrophotometer at 266nm, followed by refilling fresh 10ml buffer.

18 In the analysis of encapsulation efficiency, beads were suspended in pH2 buffer
19 with continuous shaking at 37 °C for 24 hours, where a part of encapsulated tetracycline
20 was released. Then, the beads were completely broken by using ultrasonic shaker for
21 30 minutes, and the residual tetracycline would be completely released. After the
22 solution was filtrated, UV/VIS spectrophotometer was applied to quantify tetracycline

1 in buffer by deducting the absorbance at 266 nm, allowing the determination of
2 encapsulation efficiency as following equation.

$$3 \quad \text{Encapsulation Efficiency (EE\%)} = \frac{\text{Actual loaded drug}}{\text{Amount of drug added}} \times 100\%$$

4

5 **Cytotoxicity test**

6 MTT assay was applied to evaluate the cytotoxicity of core-shell beads. In this
7 experiment, a non-small lung cancer cell line (A549) was seeded on a 24-well plate
8 with the density of 5×10^3 cells per well. As the cell monolayer were cultured to
9 confluence, they were exposed to fluid extracts. The extracts were obtained by placing
10 the core-shell beads in culture medium (0.2 g core-shell particles in 1 ml medium) for
11 24 hours at 37°C. Each fluid extract obtained was then applied to A549 monolayer,
12 replacing the medium that had nourished the cells. The cells were then cultured with
13 extracts for 1 day. After the cell culture, the metabolic activity of A549 was determined
14 by MTT assay. The cells were incubated with 1 mg/mL of MTT for 4 hours. Then, the
15 MTT was removed and the formazan crystals were dissolved with dimethyl sulfoxide
16 for 30 min. Finally, absorbance values were read at 570 nm by using an automatic
17 microplate reader (ELx800; Bio-Tek Instruments, Winooski, VT, USA).

18

19 **Antibacterial testing**

20 LB medium (from Creative Life Science Co., Ltd.) was applied for the culture of
21 *E. coli* which was from Bioresources Conservation and Research Center (BCRC),
22 Taiwan. The medium with cultured bacterial was added onto agar plate evenly,

1 followed by an overnight culture. After that, core-shell beads were added onto the agar
2 plate, and the antibacterial effects were observed at various time points.

3

4 **Results**

5 Table 1 demonstrates the floating bead formulations. In this research, the mass
6 ratio of chitosan to xanthan gum in the shell layer was adjusted to 4:1, 4:2, 4:3, 4:4 and
7 1:4, where the amounts of salts (CaCl_2 and NaHCO_3) and alginate in core were fixed.

8 The morphologies of core-shell particles were analyzed by using SEM as shown
9 in Fig. 1(a). The beads were roughly spherical, with a diameter ranging from 1.5 to 2
10 mm. The particle diameters were analyzed using Image J and presented in Fig. 1(b).
11 The formulation of the shell layer had a weak impact on the particle morphologies and
12 diameters. The cross-sectional images of core-shell beads are presented in Fig. 2.
13 Results show that the particles prepared in this research were highly porous.

14 Fig. 3 revealed the swelling ratios of core-shell particles with different immersion
15 periods at pH 2. As shown in Fig. 3, all kinds of particles were gradually swelled during
16 first 6 h and reached a steady state over the next 2 h. The highest swelling ratios at
17 steady state were 150%-200%. Fig. 3 also shows that the particles are swelled faster
18 and steady-state swelling ratios increase when the amounts of chitosan are much higher
19 or much lower than the amounts of xanthan gum, such as chitosan:xanthan gum = 4:1
20 and 1:4. In contrast, the swelling ratios were relatively low with chitosan:xanthan gum
21 = 4:3 and 4:4.

22 Fig. 4 presents the floating percentages of core-shell beads in the aqueous solution
23 with pH 2 after immersion for different periods. Fig. 4 (a) shows that the floating
24 percentage of chitosan beads decreased to 55% after 24 h when there is no core-shell

1 structure. Results in Fig. 4 (b) show that about 90% and 88% of core-shell particles
2 would still keep their floating conditions after 8 and 24 h, respectively.

3 The encapsulation efficiency and releasing rate of tetracycline of floating beads
4 are described in Figs. 5. There is no significant difference in the encapsulation caused
5 by the ratios of chitosan and xanthan gum, as revealed in Fig. 5 (a). The release profile
6 in Fig. 5 (b) has been evaluated in dynamic conditions.

7 The results in Fig. 6 identified the good biocompatibility of floating beads when
8 the bead concentration was as high as 1.5 mg/ml, which contained 149.03 $\mu\text{g/ml}$
9 tetracycline, 112.9 times higher than the effective concentration of tetracycline for a
10 60-kg person [11].

11 The anti-bacterial effects of floating beads are proved in Fig. 7. The obvious anti-
12 bacterial rings are formed by applying beads with encapsulated tetracycline onto
13 cultured *E. coli*. It was caused by the released tetracycline, and the core-shell beads
14 without tetracycline did not result in any anti-bacterial ring (Fig. 7 (a), (b), and (c)). To
15 identify the duration of the floating particles, we immersed the particles in a pH 2-buffer
16 for 2 and 4 h before conducting the anti-bacterial experiments. The results in Figs. 7 (e)
17 and (f) proved that the beads can efficiently suppress *E. coli* though there was a pre-
18 release for 2 and 4 h. Compared with the beads without prerelease in Fig. 7 (d), the anti-
19 bacterial effect did not decay, as shown in in Figs. 7 (e) and (f).

20

21 **Discussion**

22 The densities of chitosan and xanthan gum used in this research were
23 approximately 0.3 and 1.5 g/cm^3 , respectively. The bulk densities of blended chitosan
24 and xanthan gum were approximately 1.47 g/cm^3 when the ratio was close to 1:1. After

1 get mixed, chitosan and xanthan gum demonstrated high density compared with their
2 original values. Thus, we assume that interactions between chitosan and xanthan gum
3 increase the density of the two components. The anionic polymer chains of xanthan
4 gum and protonated chitosan exert high intermolecular forces because of the electro-
5 affinity. Polymer interactions make the shell layer dense.

6 According to SEM images, the bead surfaces are dense, which would prolong
7 floating periods due to the resistance of mass transfer in water penetration. The dense
8 skin layer could help prolong the release time of encapsulated drugs. The
9 chitosan/xanthan-gum ratios did not significantly affect the porosity of core-shell beads.

10 Since the positive charges of chitosan and negative charges of xanthan gum would
11 result in a strong polymer interaction. These interactions make the shell layer dense,
12 forming a resistance of mass transfer in the shell layer. This hinders water penetration
13 into particles, and therefore, the swelling ratio is low. This result in Fig.3 revealed that
14 the particle swelling can be tuned by controlling the electro-statistical properties of the
15 shell layer. Besides, the high swelling ratios of core-shell beads show that all the beads
16 developed in this research are very hydrophilic. The hydrophilic particles can provide
17 good encapsulation efficiency and release profile due to the high affinity between the
18 drugs and particles.

19 The retention periods of FDDS in the stomach reported in previous studies were
20 about 2-4 h [12]. The floating time of core-shell particles was much longer than the
21 above residual periods, indicating the dense shell layer developed in this research can
22 prolong the floating time of drugs in the stomach.

23 When the amounts of chitosan are much higher or much lower than xanthan gum
24 (chitosan:xanthan gum = 4:1 and 1:4), the release of tetracycline is also higher than

1 those from chitosan:xanthan-gum=4:3 and 4:4. This is due to the strong interactions
2 between positive chitosan and negative xanthan gum, which results in a dense shell
3 layer. With the dense shell layer, the particle swelling is slow, and the tetracycline
4 release is delayed due to the high resistance in mass transfer. The results supported that
5 the prolonged release can be achieved by controlling the formulation of the dense layer
6 in the core-shell floating beads.

7 The floating beads are proved to be biocompatible, and can carry effective
8 antibiotics when they were applied. The released tetracycline from core-shell beads
9 present clear antibacterial effects. This supports that the core-shell beads developed in
10 this research can continuously delivery antibiotics for a certain period.

11

12 **Conclusion**

13 In this research, we developed core-shell floating beads for GDDS with porous
14 alginate core and a dense chitosan/xanthan-gum shell layer. The compactness of the
15 shell layer in floating beads was controlled by adjusting the ratios of anionic xanthan
16 gum and cationic chitosan. When the chitosan/xanthan gum ratio was 4:3 and 4:4, the
17 shell layer would be dense and would cause high resistance of mass transfer under the
18 water penetration. Thus, a low swelling rate and a prolonged release was achieved. The
19 experimental results proved the high biocompatibility of the floating beads, and the
20 anti-bacterial effects of beads were also significant after the release for 4 h. This study
21 proposed the method to modify the properties of shell layer, allowing the control of the
22 swell and release behaviors of floating beads.

23

24

1 **Abbreviations**

2 **GDDS:** Gastroretentive drug delivery system

3 **SEM:** scanning electron microscopy

4 **FDSD:** floating drug delivery system

5 **HBS:** hydrodynamically balanced system

6 **DMEM:** Dulbecco's modified eagle medium

7 **FBS:** fetal bovine serum

8

9 **Declarations**

10 **Ethics approval and consent to participate**

11 Not applicable.

12 **Consent for publication**

13 Not applicable.

14 **Availability of data and materials**

15 All data generated or analyzed in this study are included in this published article.

16 **Competing interests**

17 The authors declare that they have no competing interests.

18 **Funding**

19 This work was financially supported by National Science Council, Taiwan (NSC, No.

20 108-2221-E-011-107-) and by National Taiwan University of Science and Technology

21 (NTUST).

1 **Authors' contributions**

2 Ming-Hua Ho and Chen-Yu Kao designed this research. Yu-Tung Hsu performed the
3 experiments. Ming-Hua Ho, Yu-Tung Hsu and Chen-Yu Kao wrote the manuscript.
4 Ming-Hua Ho supervised the project and reviewed the manuscript. All authors
5 contributed to the article and approved the submitted version.

6 **Acknowledgements**

7 The authors would like to thank Precious Instrumentation Center of NTUST for the
8 assistances in SEM set up.


9

10 **References**


- 11 [1] S.S. Patel, S. Ray, R.S. Thakur, Formulation and evaluation of floating drug
12 delivery system containing clarithromycin for *Helicobacter pylori*, *Acta Pol.*
13 *Pharm.*, 63 (2006) 53-61.
- 14 [2] R.M. Amit Kumar Nayak, D. Biswarup, Gastroretentive drug delivery systems: a
15 review, *Asian J. Pharm. Clin. Res.*, 3 (2010) 2-10.
- 16 [3] S. Arora, J. Ali, A. Ahuja, R.K. Khar, S. Baboota, Floating drug delivery systems:
17 a review, *AAPS PharmSciTech.*, 6 (2005) E372-E390.
- 18 [4] M.D. Burkitt, C.A. Duckworth, J.M. Williams, D.M. Pritchard, *Helicobacter*
19 *pylori*-induced gastric pathology: insights from in vivo and ex vivo models,
20 *Disease models & mechanisms*, 10 (2017) 89-104.
- 21 [5] J.G. Kusters, A.H. Van Vliet, E.J. Kuipers, Pathogenesis of *Helicobacter pylori*
22 infection, *Clin. Microbiol. Rev.*, 19 (2006) 449-490.
- 23 [6] D.Y. Graham, *Helicobacter pylori* update: gastric cancer, reliable therapy, and
24 possible benefits, *Gastroenterology*, 148 (2015) 719-731.
- 25 [7] R. Bansil, J.P. Celli, J.M. Hardcastle, B.S. Turner, The influence of mucus
26 microstructure and rheology in *Helicobacter pylori* infection, *Frontiers in*
27 *immunology*, 4 (2013) 310.
- 28 [8] X. Xu, M. Sun, F. Zhi, Y. Hu, Floating matrix dosage form for phenoprolamine
29 hydrochloride based on gas forming agent: In vitro and in vivo evaluation in
30 healthy volunteers, *Int. J. Pharm.*, 310 (2006) 139-145.
- 31 [9] B. Choi, H.J. Park, S. Hwang, J. Park, Preparation of alginate beads for floating

- 1 drug delivery system: effects of CO₂ gas-forming agents, *Int. J. Pharm.*, 239
2 (2002) 81-91.
- 3 [10] A. El-Kamel, M. Sokar, S. Al Gamal, V. Naggar, Preparation and evaluation of
4 ketoprofen floating oral delivery system, *Int. J. Pharm.*, 220 (2001) 13-21.
- 5 [11] M.J. Ferrua, R.P. Singh, Human gastric simulator (Riddet model), *The impact of*
6 *food bioactives on health*, 2015, pp. 61-71.
- 7 [12] B.N. Singh, K.H. Kim, Floating drug delivery systems: an approach to oral
8 controlled drug delivery via gastric retention, *J. of Control. Release*, 63 (2000)
9 235-259.


Figures




Chitosan : Xanthan =4:1



Chitosan : Xanthan =4:2



Chitosan : Xanthan =4:3



Chitosan : Xanthan =4:4



Chitosan : Xanthan =1:4






Figure 1

Morphologies of core-shell floating beads with various formulation in chitosan/xanthangum shell layer. (a) SEM images of floating beads. The chitosan : xanthan gum ratios are 4:1 (A), 4:2 (B), 4:3 (C), 4:4 (D) and 1:4 (E). (b) Diameters of beads with various formulations in chitosan/xanthan-gum shell layer


Chitosan : Xanthan =4:1




Chitosan : Xanthan =4:2



Chitosan : Xanthan =4:3



Chitosan : Xanthan =4:4



Chitosan : Xanthan =1:4




Figure 2

The cross-sectional images of floating beads with various formulation in chitosan/xanthan gum shell layer






Figure 3

The swelling ratios of core-shell beads with various formulation in chitosan/xanthan-gum in pH=2 buffer. The times for immersion were 1, 2, 4, 6, 8, 12 and 24 hours.




(a)




(b)

Figure 4

The floating percentage of (a) Chitosan beads without core-shell structure and (b) Coreshell beads with various chitosan/xanthan gum ratios



(a)



(b)

Figure 5

Encapsulation efficiency (a) and releasing profile (b) of tetracycline-alginate floating beads in pH=2 buffer




Figure 6

Biocompatibility of floating beads. The bead amounts in culture medium were 0.5, 1 and 1.5 mg/ml, respectively. TCPS was tissue culture polystyrene which was used as the controlled group. The culture period was 24 hours.




Figure 7

Antibacterial effects of floating beads with/without tetracycline for different immersion periods. (a), (b) and (c) are core-shell beads without tetracycline, and (d), (e) and (f) are beads with tetracycline. The immersion time before antibacterial test is 0 hour for (a) (d), 2 hours for (b) (e), and 4 hours for (c) (f). . The chitosan : xanthan gum ratios are 4:3

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [Tables.pdf](#)